A quiet 48 hours for WHO and foreign aid news left the FDA’s venglustat approval, Anthropic’s record IPO and a fraud-prevention campaign as the clearest developments touching health, capital and security.
A search of the past 48 hours of headlines for the World Health Organization, pandemic preparedness, climate adaptation in Africa and foreign aid returned nothing on those subjects. The material that did surface touches global health only at the edges. It is reported here as it stands, without stretching it into a larger narrative.
The most concrete item is regulatory. The FDA approved Sanofi’s Infilbray (venglustat) on November 18 as the first treatment for the neurological symptoms of type 3 Gaucher disease. The indication covers adults and pediatric patients weighing at least 15 kilograms. According to the agency, the supporting randomized study enrolled 43 patients aged 12 and older and compared once-daily oral treatment with enzyme-replacement therapy over 52 weeks.
Sanofi reported that its Phase 3 LEAP2MONO study showed statistically significant superiority across multiple neurological endpoints, with a p-value of 0.0137. The FDA-listed risks are substantial: gastrointestinal and mood-related effects, serious psychiatric risks including suicidal ideation and behavior, possible lens clouding in younger patients and risks to fetal development. A 43-patient trial is small by any standard, which is typical for a rare-disease approval. Neither the agency’s statement nor the coverage reviewed here addresses pricing or how many American patients would qualify.
Other medical research in the window was earlier-stage. A study published November 19 in Science Translational Medicine found more frequent sleep-like slow brain waves in 84 people with Parkinson’s disease without dementia than in 30 healthy older adults. The changes were associated with hallucinations and poorer cognitive performance. That is an association in a modest sample, not a treatment. A separate report from Oslo University Hospital researchers described work in roundworms, where switching off a specific gene protected one type of nerve cell from age-related degeneration. Whether that translates to humans is an open question.
The larger story on the capital side is private. Anthropic priced its IPO at $83 per share, offering 980 million shares and raising $81.3 billion at a $1.5 trillion valuation, according to Reuters and CNN. That surpassed the $75 billion SpaceX raised in June. Business Standard reported a separate $26 billion private placement involving major technology companies, bringing total financing to $107.3 billion. Bloomberg said shares were indicated to open 25% above the offering price, while Bloomberg Law put indicative interest near $105, about 27% higher. The figures differ slightly by outlet and by the time of the indication. The shares were scheduled to trade on Nasdaq under the ticker ANT.
The relevance to the global-health beat is indirect. The scale of private capital that markets can mobilize for a single enterprise is a fact worth setting beside multilateral funding debates, though nothing in the reviewed material draws that comparison, and no health spending figures were available for it.
On security, Craigslist founder Craig Newmark told Business Insider he is promoting the Take9 campaign’s advice to pause and count to nine before responding to suspicious messages. He pointed to deepfake voice scams and fake family emergency calls. He also recommended passkeys, password managers, single sign-on and multifactor authentication. A November 10 campaign report said people who saw its “Count Before You Click” effort felt 48% more confident about avoiding fraud, and traffic to its safety resources rose 1,200%. Those are the campaign’s own numbers, and they measure confidence and web traffic, not fraud losses avoided.
The Register separately reported that Equinor, described as Europe’s biggest gas supplier, is battling a cyberattack with no recovery timeline, though the Norwegian company says oil and gas production is unaffected.
For American readers, the direct stake is narrow. The venglustat approval is a U.S. regulatory decision with a defined patient group. The rest of the day’s material is a reminder that the WHO and foreign-aid debates will need fresh reporting rather than inference from an unrelated news cycle.

